FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997092421> ?p ?o ?g. }

• W1997092421 endingPage "824" @default.
• W1997092421 startingPage "819" @default.
• W1997092421 abstract "To evaluate neonatal screening for cystic fibrosis (CF), including study of the screening procedures and characteristics of false-positive infants, over the past 10 years in Wisconsin. An important objective evolving from the original design has been to compare use of a single-tier immunoreactive trypsinogen (IRT) screening method with that of a two-tier method using IRT and analyses of samples for the most common cystic fibrosis transmembrane regulator (CFTR) (DeltaF508) mutation. We also examined the benefit of including up to 10 additional CFTR mutations in the screening protocol.From 1985 to 1994, using either the IRT or IRT/DNA protocol, 220 862 and 104 308 neonates, respectively, were screened for CF. For the IRT protocol, neonates with an IRT >/=180 ng/mL were considered positive, and the standard sweat chloride test was administered to determine CF status. For the IRT/DNA protocol, samples from the original dried-blood specimen on the Guthrie card of neonates with an IRT >/=110 ng/mL were tested for the presence of the DeltaF508 CFTR allele, and if the DNA test revealed one or two DeltaF508 alleles, a sweat test was obtained.Both screening procedures had very high specificity. The sensitivity tended to be higher with the IRT/DNA protocol, but the differences were not statistically significant. The positive predictive value of the IRT/DNA screening protocol was 15.2% compared with 6.4% if the same samples had been screened by the IRT method. Assessment of the false-positive IRT/DNA population revealed that the two-tier method eliminates the disproportionate number of infants with low Apgar scores and also the high prevalence of African-Americans identified previously in our study of newborns with high IRT levels. We found that 55% of DNA-positive CF infants were homozygous for DeltaF508 and 40% had one DeltaF508 allele. Adding analyses for 10 more CFTR mutations has only a small effect on the sensitivity but is likely to add significantly to the cost of screening.Advantages of the IRT/DNA protocol over IRT analysis include improved positive predictive value, reduction of false-positive infants, and more rapid diagnosis with elimination of recall specimens." @default.
• W1997092421 created "2016-06-24" @default.
• W1997092421 creator A5021495934 @default.
• W1997092421 creator A5027223018 @default.
• W1997092421 creator A5034330742 @default.
• W1997092421 creator A5045963637 @default.
• W1997092421 creator A5048344519 @default.
• W1997092421 creator A5049871412 @default.
• W1997092421 creator A5055381394 @default.
• W1997092421 creator A5071169814 @default.
• W1997092421 creator A5072965164 @default.
• W1997092421 creator A5077871444 @default.
• W1997092421 creator A5084583190 @default.
• W1997092421 date "1997-06-01" @default.
• W1997092421 modified "2023-09-25" @default.
• W1997092421 title "Newborn Screening for Cystic Fibrosis in Wisconsin: Comparison of Biochemical and Molecular Methods" @default.
• W1997092421 cites W1547921699 @default.
• W1997092421 cites W1934589322 @default.
• W1997092421 cites W1939087218 @default.
• W1997092421 cites W1965732133 @default.
• W1997092421 cites W1968403864 @default.
• W1997092421 cites W1969504328 @default.
• W1997092421 cites W1986682462 @default.
• W1997092421 cites W1988961373 @default.
• W1997092421 cites W2003559527 @default.
• W1997092421 cites W2004510058 @default.
• W1997092421 cites W2011727906 @default.
• W1997092421 cites W2019955688 @default.
• W1997092421 cites W2030789701 @default.
• W1997092421 cites W2035784150 @default.
• W1997092421 cites W2068076344 @default.
• W1997092421 cites W2073009316 @default.
• W1997092421 cites W2088769712 @default.
• W1997092421 cites W2094966201 @default.
• W1997092421 cites W2112665737 @default.
• W1997092421 cites W2125391335 @default.
• W1997092421 cites W2152290671 @default.
• W1997092421 cites W2158769256 @default.
• W1997092421 doi "https://doi.org/10.1542/peds.99.6.819" @default.
• W1997092421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9164776" @default.
• W1997092421 hasPublicationYear "1997" @default.
• W1997092421 type Work @default.
• W1997092421 sameAs 1997092421 @default.
• W1997092421 citedByCount "128" @default.
• W1997092421 countsByYear W19970924212012 @default.
• W1997092421 countsByYear W19970924212013 @default.
• W1997092421 countsByYear W19970924212014 @default.
• W1997092421 countsByYear W19970924212015 @default.
• W1997092421 countsByYear W19970924212016 @default.
• W1997092421 countsByYear W19970924212017 @default.
• W1997092421 countsByYear W19970924212018 @default.
• W1997092421 countsByYear W19970924212019 @default.
• W1997092421 countsByYear W19970924212020 @default.
• W1997092421 countsByYear W19970924212021 @default.
• W1997092421 countsByYear W19970924212022 @default.
• W1997092421 countsByYear W19970924212023 @default.
• W1997092421 crossrefType "journal-article" @default.
• W1997092421 hasAuthorship W1997092421A5021495934 @default.
• W1997092421 hasAuthorship W1997092421A5027223018 @default.
• W1997092421 hasAuthorship W1997092421A5034330742 @default.
• W1997092421 hasAuthorship W1997092421A5045963637 @default.
• W1997092421 hasAuthorship W1997092421A5048344519 @default.
• W1997092421 hasAuthorship W1997092421A5049871412 @default.
• W1997092421 hasAuthorship W1997092421A5055381394 @default.
• W1997092421 hasAuthorship W1997092421A5071169814 @default.
• W1997092421 hasAuthorship W1997092421A5072965164 @default.
• W1997092421 hasAuthorship W1997092421A5077871444 @default.
• W1997092421 hasAuthorship W1997092421A5084583190 @default.
• W1997092421 hasConcept C104317684 @default.
• W1997092421 hasConcept C126322002 @default.
• W1997092421 hasConcept C180754005 @default.
• W1997092421 hasConcept C187212893 @default.
• W1997092421 hasConcept C2776169613 @default.
• W1997092421 hasConcept C2776737053 @default.
• W1997092421 hasConcept C2776938444 @default.
• W1997092421 hasConcept C2778428886 @default.
• W1997092421 hasConcept C2778764654 @default.
• W1997092421 hasConcept C2779879311 @default.
• W1997092421 hasConcept C2908647359 @default.
• W1997092421 hasConcept C54355233 @default.
• W1997092421 hasConcept C63398376 @default.
• W1997092421 hasConcept C71924100 @default.
• W1997092421 hasConcept C86803240 @default.
• W1997092421 hasConcept C99454951 @default.
• W1997092421 hasConceptScore W1997092421C104317684 @default.
• W1997092421 hasConceptScore W1997092421C126322002 @default.
• W1997092421 hasConceptScore W1997092421C180754005 @default.
• W1997092421 hasConceptScore W1997092421C187212893 @default.
• W1997092421 hasConceptScore W1997092421C2776169613 @default.
• W1997092421 hasConceptScore W1997092421C2776737053 @default.
• W1997092421 hasConceptScore W1997092421C2776938444 @default.
• W1997092421 hasConceptScore W1997092421C2778428886 @default.
• W1997092421 hasConceptScore W1997092421C2778764654 @default.
• W1997092421 hasConceptScore W1997092421C2779879311 @default.
• W1997092421 hasConceptScore W1997092421C2908647359 @default.
• W1997092421 hasConceptScore W1997092421C54355233 @default.
• W1997092421 hasConceptScore W1997092421C63398376 @default.
• W1997092421 hasConceptScore W1997092421C71924100 @default.

• next